Oncolytic Virus Drug Products: Building CMC Under the Current FDA CBER OTP and EMA CAT Frameworks
Oncolytic viruses sit at an unusually demanding CMC intersection: the product must retain a defined viral identity and engineered genotype, reproduce consistently, express any therapeutic transgene as intended, demonstrate biological…
On this pageArticle overview
Oncolytic Virus Drug Products: Building CMC Under the Current FDA CBER OTP and EMA CAT Frameworks
Oncolytic viruses sit at an unusually demanding CMC intersection: the product must retain a defined viral identity and engineered genotype, reproduce consistently, express any therapeutic transgene as intended, demonstrate biological potency, and maintain an acceptable safety profile without allowing manufacturing variability to erode the tumor-selective mechanism.
The regulatory architecture must also be current. FDA’s former Office of Cellular, Tissue, and Gene Therapies and later Office of Tissues and Advanced Therapies were reorganized; CBER now regulates gene therapies through the Office of Therapeutic Products (OTP), which includes the Office of Gene Therapy Chemistry, Manufacturing and Controls. Oncolytic viral products should therefore be framed through current CBER/OTP gene-therapy CMC expectations rather than the obsolete Office of Therapeutic Products (OTP) organizational label. In Europe, the EMA Committee for Advanced Therapies (CAT) remains central to advanced-therapy classification and assessment, and the current investigational ATMP guideline became effective July 1, 2025.
Virus Seed and Cell-Substrate Strategy: Genetic Identity Must Be Controlled Across the Manufacturing Lineage
An oncolytic-virus manufacturing program needs a clearly defined seed-lot system and, where applicable, a controlled production-cell substrate. The CMC question is not whether the seed tests positive for the correct virus. It is whether the seed and production system together provide a traceable, genetically stable starting point capable of reproducibly generating product with the intended identity, purity, safety, and potency.
Characterization should be product specific. Sequence analysis can be important where engineered deletions, insertions, promoter modifications, or transgenes define the mechanism of action. The appropriate sequencing depth, acceptance strategy, and variant-analysis method should be justified for the viral platform and the risk of genetic drift rather than copied as a universal numerical threshold. Passage-history studies should demonstrate that critical genomic features and phenotypic attributes remain acceptably stable across the manufacturing range.
Adventitious-agent control should integrate starting-material qualification, cell-bank and viral-seed testing, raw-material controls, manufacturing process barriers, and the current viral-safety framework applicable to the substrate and platform. ICH Q5A(R2), together with product-specific gene-therapy guidance, should be applied in a way that reflects the actual biological system rather than forcing a protein-biologic template onto a replicating or replication-selective viral product.
Replication Competence and Replication Selectivity: Do Not Confuse the Safety Question With a Generic Assay
Replication-related testing is highly vector specific. For a replication-defective vector, the key question may be detection of replication-competent virus generated through recombination or manufacturing contamination. For a deliberately replication-competent or replication-selective oncolytic virus, the relevant control strategy is different: the product is designed to replicate, so the CMC and nonclinical evidence must demonstrate that the engineered replication phenotype remains consistent with the intended selectivity and safety design.
The assay system, reference material, positive control, sensitivity, specificity, and acceptance logic should therefore be linked to the biology of the platform. Fixed cross-platform numerical limits are inappropriate unless supported by product-specific precedent and method capability. FDA’s existing replication-competent retrovirus guidance is useful for understanding the general regulatory logic of sensitive detection and manufacturing control, but an adenovirus, HSV, poxvirus, or other oncolytic platform requires its own scientifically justified strategy.
Potency: Move From Viral Quantity to Biological Function
Infectious titer is a critical product attribute, but it does not necessarily measure the full biological activity of an oncolytic virus. Potency strategy should connect the product’s mechanism of action to one or more quantitative assays capable of demonstrating relevant biological function. Depending on the product, that may involve infection, replication, tumor-cell killing, transgene expression, immune activation, or an assay matrix combining complementary functions.
FDA’s 2020 gene-therapy CMC guidance expects sufficient CMC information to assure safety, identity, quality, purity, and strength, including potency. FDA’s 2023 draft guidance on Potency Assurance for Cellular and Gene Therapy Products further emphasizes a science- and risk-based potency assurance strategy. In May 2026 FDA finalized guidance on CMC flexibilities for CGT BLA development, but flexibility does not mean weak potency control. It means the extent and timing of evidence may be tailored to product understanding, development stage, and risk.
A phase-appropriate potency program should therefore evolve without creating a late-stage analytical cliff. Early surrogate assays can be acceptable where scientifically justified, but the development plan should define how the assay strategy will mature toward a mechanism-relevant, stability-indicating, quantitatively controlled potency framework capable of supporting licensure and lifecycle management.
Armed Oncolytic Viruses: Transgene Identity, Expression, and Genetic Stability
For armed oncolytic viruses, the therapeutic transgene creates an additional CMC layer. The sponsor must understand whether the inserted sequence is genetically stable, whether expression is consistent, whether the transgene alters viral fitness or product heterogeneity, and whether manufacturing passage can select variants with changed expression. Appropriate controls may include sequence verification, copy-number or genome-structure assessment, expression testing, passage-stability studies, and orthogonal characterization of the expressed product where it materially contributes to potency or safety.
These controls should be integrated rather than scattered across disconnected assays. A strong control strategy shows how viral identity, infectious activity, transgene expression, product purity, and biological potency collectively define the product.
Shedding and Environmental/Patient Interface
Oncolytic products also raise development questions outside conventional batch-release testing. FDA’s 2015 guidance on shedding studies for virus- or bacteria-based gene therapy and oncolytic products provides a framework for evaluating release of the administered organism from the patient. Shedding is not itself a manufacturing specification, but CMC attributes such as replication phenotype, infectivity, dose, formulation, and viral stability can influence the clinical shedding assessment. Development teams should ensure that CMC, nonclinical, and clinical strategies remain aligned.
EU ATMP Strategy and CAT Interface
In Europe, oncolytic-virus classification and development should be assessed under the applicable ATMP framework. CAT is responsible for assessing the quality, safety, and efficacy of advanced-therapy medicines, and its current activities include ongoing guidance development for gene-editing and other advanced modalities. The 2025 guideline on quality, non-clinical and clinical requirements for investigational ATMPs provides current expectations for clinical-trial development. Product classification should be confirmed based on the actual mechanism, genetic modification, and regulatory definition rather than assumed solely from the word “oncolytic.”
XGene Oncolytic Virus CMC Architecture
Layer 1 ā Platform and Regulatory Classification: Define the viral platform, replication design, genetic modifications, transgene function, intended mechanism, and current FDA/EMA regulatory pathway. Confirm the responsible FDA CBER OTP review framework and EU ATMP classification strategy.
Layer 2 ā Seed, Cell Substrate, and Genetic Stability: Establish controlled seed and cell-bank systems, genomic identity, passage history, adventitious-agent strategy, and evidence that critical engineered attributes remain stable through the manufacturing lineage.
Layer 3 ā Replication and Safety Controls: Build vector-specific assays that distinguish intended replication biology from unwanted replication-competent contaminants, reversion, or loss of selectivity. Validate the assay system at the sensitivity needed for the actual product risk.
Layer 4 ā Potency Assurance: Connect mechanism of action to a phase-appropriate assay matrix spanning infectious activity and the relevant functional endpoint. Plan assay evolution early enough to avoid a late-stage potency gap.
Layer 5 ā Transgene and Lifecycle Control: For armed viruses, control transgene identity, expression, and stability; integrate comparability, process change, specifications, and postapproval knowledge into the lifecycle strategy.
For XGene, the business opportunity is a specialized CMC readiness assessment for oncolytic-virus programs before pre-IND, major phase transition, PPQ planning, or BLA preparation. The value is in identifying where a conventional biologics template fails to address viral genetics, replication biology, mechanism-linked potency, and gene-therapy-specific regulatory expectations before those gaps become agency questions.
FDA, Establishment of the Office of Therapeutic Products ā https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/establishment-office-therapeutic-products
FDA, CMC Information for Human Gene Therapy INDs, January 2020 ā https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug
FDA, Potency Assurance for Cellular and Gene Therapy Products, Draft, December 2023 ā https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-assurance-cellular-and-gene-therapy-products
FDA, CMC Flexibilities for Developing Human Cellular and Gene Therapy Products for a BLA, May 2026 ā https://www.fda.gov/regulatory-information/search-fda-guidance-documents/chemistry-manufacturing-and-controls-flexibilities-developing-human-cellular-and-gene-therapy
FDA, Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products, August 2015 ā https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-and-analysis-shedding-studies-virus-or-bacteria-based-gene-therapy-and-oncolytic-products
EMA, Committee for Advanced Therapies ā https://www.ema.europa.eu/en/committees/committee-advanced-therapies-cat
EMA, Guideline on Quality, Non-clinical and Clinical Requirements for Investigational ATMPs, effective July 2025 ā https://www.ema.europa.eu/en/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal-products-clinical-trials-scientific-guideline
Regulatory architecture updated from obsolete Office of Therapeutic Products (OTP) terminology to current CBER OTP / Office of Gene Therapy CMC framework.